Morrison D C, Louis J A, Weigle W O
Immunology. 1976 Mar;30(3):317-23.
The ability of preparations of cobra factor (CoF) to convert C3 via the properdin pathway (anticomplementary activity) has been demonstrated to be unrelated to its ascribed ability to convert a tolerogenic signal into an immunogenic stimulus (adjuvant activity). It has been shown that CoF preparations which have become inactive with regard to anticomplementary activity still retain full adjuvant properties. Further, when both activities are present in preparations of CoF, they can be separated by gel filtration chromatography into a fraction with approximate molecular weight 150,000 which contains anticomplementary activity and a fraction with approximate molecular weight 20,000, which contains adjuvant properties.
眼镜蛇因子(CoF)制剂通过备解素途径转化C3的能力(抗补体活性)已被证明与其将致耐受性信号转化为免疫原性刺激的假定能力(佐剂活性)无关。已表明,在抗补体活性方面已失活的CoF制剂仍保留完全的佐剂特性。此外,当CoF制剂中同时存在这两种活性时,它们可通过凝胶过滤色谱法分离成一个分子量约为150,000的含有抗补体活性的级分和一个分子量约为20,000的含有佐剂特性的级分。